Xenetic Biosciences (XBIO) Total Debt to Capital

Xenetic Biosciences (XBIO) is developing cell therapy systems, leveraging licensing fees from its patents. The company competes in the field of chemotherapy enhancement, utilizing its intellectual property to attract investment. The production cycle relies on third-party contractors in the US, which reduces capital expenditures. This daily price chart illustrates a debt-to-equity ratio of 0.00.

The assessment of Xenetic Biosciences (XBIO) margin of safety is based on the ratio of total debt to equity, which determines the degree of financial independence and the risk of bankruptcy during market downturns. By analyzing the trend of the company's total liabilities-to-equity ratio, an investor can see how effectively robotic small-molecule screening enables the scaling of drug development without overloading the balance sheet with excessive leverage.